---
schema_version: "1.0.0"
document_id: "30608e9e151f369f4457de7c98df425ca173819c22e3352aefaf9e360d35fb6e"
company_key: "certara-inc-common-stock"
company: "Certara Inc."
source_id: "certara-inc-common-stock-rss-c7049147c8d2"
canonical_url: "https://www.certara.com/blog/why-speed-and-scale-matter-in-your-discovery-pipeline-a-scalable-compound-registration/"
published_at: "2026-08-06T14:36:21+00:00"
first_seen_at: "2026-08-06T15:09:24.055468+00:00"
fetched_at: "2026-08-06T15:09:26.016402+00:00"
content_hash: "sha256:a58e451dfbb77432af81dae9b27a1d7b64957a9677f8edadde26f9ee6a2443f0"
---

# Why speed and scale matter in your discovery pipeline – A scalable compound registration

ShareShareShare


Anikó Horváth-Farkas Product Marketing Manager


August 6, 2026


Every new compound that enters a pharmaceutical or biotech organization’s database must clear one critical gate before it can be used: registration. It’s the process that checks a structure against everything already known within the organization, assigns it an identity, and makes it discoverable to every downstream system, from electronic lab notebooks to analytics platforms.


It sounds like a back-office task. In practice, it’s a make-or-break piece of R&D infrastructure. When registration is fast and reliable, scientists get compounds into their hands quickly. When it isn’t, everything downstream slows down with it.


We’ve spent the past two years asking ourselves a hard question about our own platform: as our customers’ compound libraries grew into the tens of millions, was our architecture built for scalable compound registration? That question led to a systematic, version-over-version rebuild of the[Compound Registration](https://www.certara.com/compound-registration/) engine. The performance gains that came out of it are the reason we’re writing this post.


## Why this problem gets harder as you grow


The tricky part about compound registration performance is that it doesn’t stay constant. As a compound database grows from hundreds of thousands to tens of millions of structures, the computational cost of checking a new compound against everything that came before grows too. A system that performs well at a modest scale can hit a wall once a company’s compound collection crosses into the tens of millions. This is precisely the point where many established pharmaceutical organizations find themselves today.


Modern R&D organizations increasingly work with more CRO partners, and more downstream systems that need to be kept in sync in near real time. Each of those factors adds computational overhead. A registration platform has to be engineered to keep pace with all of it simultaneously.


## What changes when you solve it


Compound registration performance is a solvable engineering problem, and the improvements are measurable. Organizations that invest in modern, purpose-built registration architecture have seen bulk upload times that once took the better part of a working day come down to a matter of. Similar gains show up in support for complex hierarchies, where uploads that previously bottlenecked on locking and concurrency issues now complete without the same slowdown.


That kind of improvement isn’t just an IT win. It’s the difference between a CRO delivery that’s ready to work with the same day and one that’s still processing tomorrow. It’s the difference between a compound library migration that fits in a weekend and one that stretches across a quarter.


## What to look for in a modern registration platform


If you’re evaluating or planning to scale your own compound registration infrastructure, a few questions are worth asking:


- How does the performance scale? Does it degrade sharply as the database grows?
- How is infrastructure sized for your workload?
- Can the system handle complex compound hierarchies gracefully?
- What happens to downstream publishing under load?


Near-linear scaling, database performance, multiple lots of batches per parent structure, integrated applications kept in sync, … These aren’t abstract technical details. They translate directly into how confidently your organization can plan a compound library migration, onboard a new CRO relationship, or support a merger without disrupting ongoing science.


## See the full benchmark data


We measured our own progress in detail, so you don’t have to take our word for it: version-over-version speed improvements, performance across database sizes from one million to over sixty million compounds, infrastructure sizing guidance, and the impact of features like downstream publishing and concurrent uploads.


The complete picture with full benchmark tables, methodology, and infrastructure recommendations is available in our white paper,[“Certara Compound Registration Performance: Scalability and Speed Across Enterprise Deployments”](https://www.certara.com/white-paper/certara-compound-registration-performance-scalability-and-speed-across-enterprise-deployments)


White paper


## Certara Compound Registration Performance: Scalability and Speed Across Enterprise Deployments


See the complete performance data and start planning a registration architecture that scales with your science, not against it.


[Download the full white paper](https://www.certara.com/white-paper/certara-compound-registration-performance-scalability-and-speed-across-enterprise-deployments/)


## Author


[Anikó Horváth-Farkas](https://www.certara.com/teams/aniko-horvath-farkas/) Product Marketing Manager


Anikó is a Product Marketing Manager for Certara’s Discovery portfolio, connecting drug discovery professionals with technologies that accelerate their path from compound to candidate.


## You May Also Like


AllCheminformatics


[Precursor chemicals – Sine qua non](https://www.certara.com/blog/precursor-chemicals-sine-qua-non/)


[Precursor chemicals – Sine qua non](https://www.certara.com/blog/precursor-chemicals-sine-qua-non/)[Blog](https://www.certara.com/category/blog/)


### [Precursor chemicals – Sine qua non](https://www.certara.com/blog/precursor-chemicals-sine-qua-non/)


[The psychedelic executive order and the new U.S. push on psychedelic research and what it actually means for scientists](https://www.certara.com/blog/psychedelic-executive-order-psychedelics-research/)


[The psychedelic executive order and the new U.S. push on psychedelic research and what it actually means for scientists](https://www.certara.com/blog/psychedelic-executive-order-psychedelics-research/)[Blog](https://www.certara.com/category/blog/)


### [The psychedelic executive order and the new U.S. push on psychedelic research and what it actually means for scientists](https://www.certara.com/blog/psychedelic-executive-order-psychedelics-research/)


[Certainty Discovery. Frankfurt, November 4-5, 2025](https://www.certara.com/blog/certainty-discovery-2025-wendy-warr-review/)


[Certainty Discovery. Frankfurt, November 4-5, 2025](https://www.certara.com/blog/certainty-discovery-2025-wendy-warr-review/)[Blog](https://www.certara.com/category/blog/)


### [Certainty Discovery. Frankfurt, November 4-5, 2025](https://www.certara.com/blog/certainty-discovery-2025-wendy-warr-review/)
